MedPath

Levosimendan

Generic Name
Levosimendan
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C14H12N6O
CAS Number
141505-33-1
Unique Ingredient Identifier
C6T4514L4E
Background

Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. It also relaxes vascular smooth muscle by opening adenosine triphosphate sensitive potassium channels. Levosimendan is used to manage acutely decompensated congestive heart failure.

Indication

For short term treatment of acutely decompensated severe chronic heart failure (CHF). Also being investigated for use/treatment in heart disease.

Associated Conditions
Acute Decompensated Heart Failure (ADHF), Acute Decompensation of Chronic Heart Failure, Acute Heart Failure (AHF), Chronic Heart Failure (CHF), Acute post-surgical heart failure, Acute, chronic Decompensated Heart Failure, Heart failure post-myocardial infarction, Severe Decompensated Chronic Heart Failure
Associated Therapies
Positive cardiac inotropic effect, Intravenous inotropic therapy
Clinical Trials
Related News

Intracoronary Administration of Levosimendan in Cardiac Surgery Patients

Phase 4
Terminated
Conditions
Myocardial Stunning
Interventions
Drug: levosimendan
Drug: Vitamin B 12
First Posted Date
2011-12-28
Last Posted Date
2019-09-13
Lead Sponsor
Tampere University Hospital
Target Recruit Count
50
Registration Number
NCT01500785
Locations
🇫🇮

Heart Center Co. Tampere university hospital, Tampere, Finland

Efficacy and Safety of Levosimendan in Severe Acute Heart Failure in Critical Children

Phase 2
Terminated
Conditions
Acute Heart Failure
Interventions
Drug: Levosimendan
Drug: Conventional intensified inotropic treatment
First Posted Date
2011-02-23
Last Posted Date
2013-01-31
Lead Sponsor
Jose Luis Vazquez Martinez
Target Recruit Count
116
Registration Number
NCT01301313
Locations
🇪🇸

Hospital Donosti, Donostia, San Sebastian, Spain

🇪🇸

Hospital Clínico Universitario de Santiago de Compostela, A Coruña, Spain

🇪🇸

Hospital Universitario Ramon y Cajal, Madrid, Spain

and more 16 locations

ELEVATE Early LEvosimendan Vs Usual Care in Advanced Chronic hearT failurE

Phase 3
Terminated
Conditions
Advanced Chronic Heart Failure
Interventions
Drug: Diuretics
Drug: Levosimendan
First Posted Date
2011-02-04
Last Posted Date
2017-04-10
Lead Sponsor
Niguarda Hospital
Target Recruit Count
13
Registration Number
NCT01290146
Locations
🇮🇹

Ospedali Riuniti di Bergamo Cardiovascular Medicine, Bergamo, Italy

🇮🇹

Ospedale Sant'Anna Cardiology, Como, Italy

🇮🇹

Azienda Ospedaliera Niguarda Heart Failure and Heart Transplant Program, Milan, Italy

and more 19 locations

Inotropic Treatment With Levosimendan (SimdaxR)in Heart Surgery

Not Applicable
Terminated
Conditions
Cardiac Surgery
Heart Failure
Interventions
Drug: levosimendan
First Posted Date
2010-10-14
Last Posted Date
2010-11-02
Lead Sponsor
Ullevaal University Hospital
Target Recruit Count
23
Registration Number
NCT01221116
Locations
🇳🇴

Dept. of Cardiothoracic Anesthesia, Ullevål University Hospital, Oslo, Norway

The Effects of Levosimendan on Haemodynamics in Patients Undergoing Elective Aortic Valve Replacement (AVR)Together With Coronary Artery Bypass Grafting (CABG) Surgery

Phase 4
Completed
Conditions
Heart Valve Disease
Interventions
Drug: placebo
Drug: levosimendan
First Posted Date
2010-09-29
Last Posted Date
2011-09-21
Lead Sponsor
Tampere University Hospital
Target Recruit Count
24
Registration Number
NCT01210976
Locations
🇫🇮

Tampere University Hospital, Tampere, Finland

Effects of Levosimendan in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy

Phase 4
Terminated
Conditions
Diastolic Dysfunction
Left Ventricular Hypertrophy
Interventions
Drug: placebo drug
Drug: levosimendan
First Posted Date
2010-08-25
Last Posted Date
2018-12-03
Lead Sponsor
University of Aarhus
Target Recruit Count
20
Registration Number
NCT01188369
Locations
🇩🇰

Department of Anaesthesiology, Århus N, Region Midtjylland, Denmark

Levosimendan Administration in Neonates With Transposition of the Great Arteries

Phase 2
Completed
Conditions
Low Cardiac Output Syndrome
Interventions
Drug: levosimendan
Drug: placebo
First Posted Date
2010-05-10
Last Posted Date
2012-06-26
Lead Sponsor
Bambino Gesù Hospital and Research Institute
Target Recruit Count
63
Registration Number
NCT01120106
Locations
🇮🇹

Bambino Gesù Hospital, Rome, Italy

Effect of Levosimendan on Respiratory Muscle Function in Healthy Subjects

Not Applicable
Completed
Conditions
Respiratory Muscle Function
Interventions
Drug: Levosimendan
First Posted Date
2010-04-12
Last Posted Date
2011-01-20
Lead Sponsor
University Medical Center Nijmegen
Target Recruit Count
30
Registration Number
NCT01101620
Locations
🇳🇱

University Medical Center Nijmegen, Nijmegen, Gelderland, Netherlands

Efficacy and Safety of Pulsed Infusions of Levosimendan in Outpatients With Advanced Heart Failure

Phase 3
Conditions
Chronic Stable Heart Failure
Interventions
Drug: Placebo
Drug: Levosimendan
First Posted Date
2010-02-09
Last Posted Date
2010-08-30
Lead Sponsor
Medical University Innsbruck
Target Recruit Count
120
Registration Number
NCT01065194
Locations
🇦🇹

Klinikum Wels Grieskirchen, Wels, Austria

🇦🇹

Medical University Innsbruck, Innsbruck, Austria

🇦🇹

Krankenhaus der Barmherzigen Schwestern, Linz, Austria

and more 8 locations

Preoperative Levosimendan and Heart Failure

Phase 4
Withdrawn
Conditions
Heart Failure
Hip Fracture
Interventions
Drug: Levosimendan
Drug: Placebo
First Posted Date
2009-12-01
Last Posted Date
2012-12-17
Lead Sponsor
Sykehuset i Vestfold HF
Registration Number
NCT01022983
Locations
🇳🇴

Oslo University Hospital - Ullevål, Oslo, Norway

🇸🇪

Mölndal Hospital, Gothenburg, Sweden

🇸🇪

Universitety Hospital Örebro, Hudiksvall, Sweden

and more 1 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy